Allergy Immunotherapy Market Size, Share, Growth, Trends, and Global Industry Analysis: By Treatment Type (Subcutaneous Immunotherapy (SCIT), Sublingual Immunotherapy (SLIT), and Specific Immunotherapy (SIT)), By Allergy Type (Allergic Rhinitis, Asthma, Food Allergy, Venom Allergy, and Others), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy and Drug Stores, and Online Pharmacy) and Region Forecast 2020-2031  

Allergy Immunotherapy Market size was valued at US$ 2.4 billion in 2024 and is expected to reach US$ 4.4 billion by 2031, growing at a significant CAGR of 9.2% from 2025-2031. The growing occurrence of sensitivities such as allergies and ineffective treatment procedures, such as pharmacotherapy, to control the prevalence rate of allergies are the major factors boosting the adoption of the market, which is considered as a designated treatment for various types of allergies. Increasing death rates due to allergies is the main reason why the government is supporting investing in research and development to provide better and improved treatment options for patients.

Allergy immunotherapy is a treatment that prevents allergic reactions from a variety of sources, including food, grass pollen, dust, and bee venom. Allergy immunotherapy helps people with allergies such as rhinitis, asthma, and conjunctivitis, among other allergies, regulate their symptoms. Allergy immunotherapy is regular injections that gradually increase the dosage in order to create resistance in the patient. Because of the increased creation of blocking antibodies that combat the foreign chemicals that cause allergies, the patient's immunity system becomes less brittle when the dosage is gradually increased.

Key Developments:

• In January 2019, Sandoz Inc., has announced the U.S. market introduction of SYMJEP (epinephrine) 0.3 mg injection for the emergency treatment of allergic reactions (Type 1)
• In June 2018, Aimmune Therapeutics, declared phase 3 trial results for AR101, an oral immunotherapy medication focused on peanut allergies, have met all the end points required by the U.S. Food and Drug Administration (FDA)